Articles by Gateway Analytical - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Gateway Analytical

Gateway Analytical


Articles
Differentiation of Drug Particle Agglomeration in OINDPs
August 27, 2014

This whitepaper presents the results of a collaborative study with the FDA that reviewed the effects that can occur in aqueous nasal spray suspensions during long-term shipping or storage conditions. Having the knowledge of the environmental conditions and their effects on OINDPs may benefit developers of formulations containing multiple APIs and/or excipients such as nasal suspensions, dry powder inhalers, and metered dose inhalers.

Differentiation of Drug Particle Agglomeration in OINDPs
May 27, 2014

This whitepaper presents the results of a collaborative study with FDA that reviewed the effects that can occur in aqueous nasal spray suspensions during long term shipping or storage conditions. Having the knowledge of the environmental conditions and their effects on OINDPs may benefit developers of formulations containing multiple APIs and/or excipients such as nasal suspensions, dry powder inhalers, and metered dose inhalers.

Analysis of Multi-Component Engineered Particles for Inhalation
December 18, 2012

This white paper discusses using Raman Chemical Imaging as method for spatially resolved, chemically-specific analysis of particles that contain multiple active ingredients in order to verify the composition of the particles, which is critical for process optimization, and regulatory requirements. Reviews method used for determining the ratio of drug components.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here